Search Result

Results for "

HSP90 inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (4) Akt (4) Androgen Receptor (1) Antibiotic (13) Apoptosis (47) ATP-binding cassette (ABC) transporters (1) Autophagy (17) Bacterial (13) Beta-lactamase (2) c-Kit (1) c-Myc (1) Casein Kinase (1) Cathepsin (1) CDK (3) Cytochrome P450 (1) DNA/RNA Synthesis (3) Drug Metabolite (2) EGFR (5) Enterovirus (1) Epigenetic Reader Domain (2) ERK (1) Estrogen Receptor/ERR (7) FAK (1) FKBP (2) Fungal (5) HDAC (5) HIF/HIF Prolyl-Hydroxylase (2) Histone Demethylase (1) Histone Methyltransferase (1) HSP (167) HSV (1) Influenza Virus (3) Interleukin Related (2) Isotope-Labeled Compounds (4) JNK (1) Ligands for Target Protein for PROTAC (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) Mitophagy (3) Monoamine Oxidase (2) mTOR (1) Na+/K+ ATPase (1) Necroptosis (2) NF-κB (1) Orthopoxvirus (3) Parasite (2) PDHK (2) PKC (1) Potassium Channel (4) PROTACs (3) Ras (1) Reactive Oxygen Species (ROS) (2) Reference Standards (9) RIP kinase (1) Sirtuin (1) Survivin (1) Topoisomerase (1) VEGFR (2) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (159) Cardiovascular Disease (3) Endocrinology (4) Infection (26) Inflammation/Immunology (16) Metabolic Disease (5) Neurological Disease (10)
Click Chemistry:	Alkynes (2)

182

Inhibitors & Agonists

Fluorescent Dye

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: Serpin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W107935

Hsp90-IN-37	HSP	Cancer
Hsp90-IN-37 (Z-2) is a heat shock protein 90 (Hsp90) inhibitor that inhibits Hsp90 enzymatic activity by 69%. Hsp90-IN-37 has antitumor activity .

HY-11038D

Zelavespib formic 5+ Cited Publications PU-H71 formic	HSP	Cancer
Zelavespib formic (PU-H71 formic) is a potent *Hsp90* inhibitor with an IC₅₀ value of 51 nM for *Hsp90* in MDA-MB-468 cells .

HY-170895

Hsp90-IN-38	HSP Na+/K+ ATPase	Cancer
Hsp90-IN-38 (compound 20m) is a HSP90 (heat shock protein) inhibitor. Hsp90-IN-38 exhibits strong *HSP90* binding affinity with a K_d of 87 nM. Hsp90-IN-38 inhibits ATPase with an IC₅₀ of 0.13 μM. Hsp90-IN-38 inhibits HCT116, MCF-7, SKBr3, K562 and A549 cells with IC₅₀s of 0.187, 0.072, 0.105, 0.403 and 031 μM, respectively .

HY-149531

HSP90-IN-25	HSP	Cancer
HSP90-IN-25 (compound 4a) is an HSP90 inhibitor that specifically inhibits the ATPase activity of HSP90 .

HY-170326

HSP90-IN-35	Ligands for Target Protein for PROTAC HSP	Cancer
Hsp90-in-35 (Compound 379) is an inhibitor of *Hsp90. The IC₅₀* of HSP90-IN-35 for Her2 is between 0.05 and 0.5 μM. HSP90-IN-35 has antitumor activity. HSP90-IN-35 can be used to synthesize PROTAC (HY-153881) .

HY-167827

Hsp90-IN-34	HSP	Cancer
Hsp90-IN-34 (compound HAM-1) is a compound that inhibits the Aha1-Hsp90 chaperone complex with a high affinity for *Hsp90/Aha1* (K_Dapp=23.5 µM). Hsp90-IN-34 modulates the ATPase activity of *Hsp90* by affecting the interaction between *Hsp90* and Aha1 .

HY-152028

HSP90-IN-19	HSP	Infection Neurological Disease Inflammation/Immunology Cancer
HSP90-IN-19 is an effective *heat shock protein 90 (Hsp90)* inhibitor. HSP90-IN-19 has effective Hsp90 inhibitory activity with an IC₅₀ value of 0.27 μM. HSP90-IN-19 can be used for the research of viral infection, neurodegenerative disease, and inflammation .

HY-152027

HSP90-IN-18	HSP Apoptosis	Infection Neurological Disease Inflammation/Immunology Cancer
HSP90-IN-18 is an effective *heat shock protein 90 (Hsp90)* inhibitor. HSP90-IN-18 has effective Hsp90 inhibitory activity with an IC₅₀ value of 0.39 μM. HSP90-IN-18 can be used for the research of viral infection, neurodegenerative disease, and inflammation .

HY-150655

Hsp90-IN-15	HSP	Cancer
Hsp90-IN-15 is an *Hsp90* inhibitor with anticancer activity. Hsp90-IN-15 induces cell apoptosis, arrests the cell cycle at S phase and decreases the expression level of *Hsp90* in Hela cell .

HY-144724

HSP90-IN-10	HSP Apoptosis	Cancer
HSP90-IN-10 (Compound 16s) is a potent inhibitor of *HSP90. HSP90-IN-10* exhibits high antiproliferative potency against HCC1954 breast cancer cells with the IC₅₀ value of 6 µM. HSP90-IN-10 does not inhibit the growth of normal epithelial cells. HSP90-IN-10 also induces apoptosis .

HY-151337

Aha1/Hsp90-IN-1	Microtubule/Tubulin	Neurological Disease Inflammation/Immunology
Aha1/Hsp90-IN-1 (Compound 17) is an Aha1/Hsp90 complex inhibitor. Aha1/Hsp90-IN-1 disrupts Aha1/Hsp90 interactions with an IC₅₀ of 3.32 μM. Aha1/Hsp90-IN-1 inhibits tau aggregation .

HY-171755

Hsp90-IN-40	HSP	Cancer
Hsp90-IN-40 (Compound 15b) is a heat shock protein 90 (Hsp90) C-terminal inhibitor. Hsp90-IN-40 exhibits antiproliferative activity against SKBr3 and MCF-7 breast cancer cells (IC₅₀ of 2.57 µM and 2.43 µM, respectively). Hsp90-IN-40 inhibits cancer cell growth by inhibiting the Hsp90 C-terminal function, leading to Hsp90-dependent protein degradation. Hsp90-IN-40 can be used in breast cancer research .

HY-156779

HSP90-IN-27	HSP	Cancer
HSP90-IN-27 (compound 19) is an *HSP90* inhibitor .

HY-113574

HSP90-IN-29	HSP	Cancer
HSP90-IN-29 (Compound 13), a benzoxazole derivative, is a potent and selective *HSP-90* inhibitor with an IC₅₀ value of 30 nM. HSP90-IN-29 has antitumor activity .

HY-149780

Flavokawain 1i DiNap	HSP	Cancer
Flavokawain 1i (DiNap) is an *Hsp90* inhibitor. Flavokawain 1i (DiNap) has anti-cell proliferation activity and can be used in cancer research .

HY-148963

HSP90-IN-20	HSP	Cancer
HSP90-IN-20 (compound 78p) is a potent *HSP90* inhibitor with an IC₅₀ of ≤10 μM. HSP90-IN-20 has the potential for cancers research .

HY-145814

HSP90-IN-9	HSP Fungal	Infection
HSP90-IN-9 is a potent and selective *HSP90* inhibitor. HSP90-IN-9 displays a fungicidal effect in a dose-dependent manner. HSP90-IN-9 inhibits fungal biofilm formation and fungal morphological changes after being combined with FLC. HSP90-IN-9 recovers FLC resistance by down-regulating the expression of related genes (ERG11, CDR1 and CDR2) .

HY-146325

HSP90-IN-11	HSP	Cancer
HSP90-IN-11 (Compound 12c) is a potent inhibitor of *HSP90. HSP90-IN-11* displays potent HSP90α inhibition comparable to AUY-922 (Luminespib). HSP90-IN-11 shows significant antiproliferative activity in CRC and NSCLC cells in a double digit nM range. HSP90-IN-11 leads to rapid degradation of client proteins EGFR and Akt in NSCLC cells. HSP90-IN-11 induces significant accumulation of a sub-G1 phase population .

HY-161427

HSP90-IN-30	HSP HIF/HIF Prolyl-Hydroxylase	Cancer
HSP90-IN-30 (compound 3e) inhibits *HSP90* chaperone activity. HSP90-IN-30 inhibits the activity of HIF-1 transcriptional under hypoxia with an IC₅₀ value of 2.16 μM .

HY-177042

Hsp90-IN-41	HSP Fungal	Infection Cancer
Hsp90-IN-41 (Compound C1) is an inhibitor of *Hsp90* (IC₅₀ = 0.044 μM). Hsp90-IN-41 exhibits antifungal and antitumor (IC₅₀ = 0.049 μM) activities in vitro .

HY-151137

HSP90/mTOR-IN-1	mTOR HSP Apoptosis Autophagy	Cancer
HSP90/mTOR-IN-1 is a potent and orally active *Hsp90* and mTOR inhibitor with IC₅₀ values of 69 nM and 29 nM, respectively. HSP90/mTOR-IN-1 suppresses the proliferation of SW780 cells through the over-activation of the PI3K/AKT/mTOR pathway. HSP90/mTOR-IN-1 induces apoptosis and autophagy via selective Hsp90 and mTOR inhibition. HSP90/mTOR-IN-1 also has considerable in vivo anti-tumor activity. HSP90/mTOR-IN-1 can be used for researching bladder cancer .

HY-149891

HSP90-IN-23	HSP	Cancer
HSP90-IN-23 (Comp 12-1) is an inhibitor of heat shock protein 90(HSP90) with an IC₅₀ of 9 nM. HSP90-IN-23 induces apoptosis of tumor cells and arrests the tumor cell cycle in G0/G1 phase. HSP90-IN-23 can be used for cancer research .

HY-170910

Hsp90-IN-39	HSP	Cancer
Hsp90-IN-39 (Compound 16t) is a *HSP90* inhibitor with notable selectivity for the *HSP90α* isoform. Hsp90-IN-39 demonstrates significant antiproliferative activity in various cancer cell lines, including MCF-7, HCT116, SKBr3, K562, and A549. Hsp90-IN-39 holds potential for cancer research .

HY-170816

CYP51/Hsp90-IN-1	HSP Cytochrome P450 Fungal	Infection
CYP51/Hsp90-IN-1 (Compound MM4) is a dual *CYP51/Hsp90* inhibitor. CYP51/Hsp90-IN-1 shows antifungal activity against Candida albicans and effectively inhibits important fungal virulence factors. CYP51/Hsp90-IN-1 is promising for research of invasive candidiasis .

HY-168205

HSP90-IN-33	HSP Apoptosis	Cancer
HSP90-IN-33 (compound 24e) is a potent *Hsp90* inhibitor with K_d values of ≥200, 7.3 µM for Hsp90α, Hsp90β, respectively. HSP90-IN-33 induces apoptosis and cell cycle arrest at G0/G1 phase. HSP90-IN-33 decreases the protein expression of ERα, CDK4 and Akt .

HY-144650

Hsp90-Cdc37-IN-3	Apoptosis HSP	Cancer
Hsp90-Cdc37-IN-3 (Compound 9) is a novel celastrol−imidazole derivative with anticancer activity. Hsp90-Cdc37-IN-3 inhibits *Hsp90−Cdc37* by covalent-binding, and induces apoptosis .

HY-163288

EZH2/HSP90-IN-29	Histone Methyltransferase HSP Apoptosis	Cancer
EZH2/HSP90-IN-29 is a dual inhibitor for EZH2 and *HSP90, with IC₅₀s of 6.29 nM and 60.1 nM, for EZH2 and HSP90, respectively. EZH2/HSP90-IN-29* increases apoptosis/necrosis-related gene expression, induces cell cycle arrest at M phase and inhibits reactive oxygen species (ROS) catabolism pathway. EZH2/HSP90-IN-29 is able to cross the blood-brain-barrier (BBB) .

HY-148215

Hsp90-IN-17	HSP	Cancer
Hsp90-IN-17 (Example 5) is an *HSP90* inhibitor that can be used in the study of proliferative diseases, such as cancer and neurodegenerative diseases .

HY-148215A

Hsp90-IN-17 hydrochloride	HSP	Cancer
Hsp90-IN-17 (Example 5) hydrochloride is an *HSP90* inhibitor that can be used in the study of proliferative diseases, such as cancer and neurodegenerative diseases .

HY-10389

Alvespimycin 10+ Cited Publications 17-DMAG; KOS-1022; NSC 707545	HSP	Cancer
Alvespimycin (17-DMAG) is a potent inhibitor of *Hsp90, binding to Hsp90* with an EC₅₀ of 62 nM.

HY-10210

Retaspimycin Hydrochloride 4 Publications Verification IPI-504	HSP	Cancer
Retaspimycin Hydrochloride is a potent inhibitor of *Hsp90* with EC₅₀s of 119 nM for both Hsp90 and Grp9.

HY-15263

Retaspimycin	HSP	Cancer
Retaspimycin is a potent inhibitor of *Hsp90, with EC₅₀s of 119 nM for both Hsp90* and Grp9.

HY-150774

HDAC6/HSP90-IN-2	HDAC HSP Apoptosis	Cancer
HDAC6/HSP90-IN-2 (compound 6e) is a dual inhibitor of HDAC6 and *Hsp90, with IC₅₀s of 105.7 and 61 nM, respectively. HDAC6/HSP90-IN-2* can be used for the research of cancer .

HY-111414

Hsp90-Cdc37-IN-1	HSP	Cancer
Hsp90-Cdc37-IN-1 is an *Hsp90-Cdc37* interaction disruptor that inhibit cell migration and reverse agent resistance, with an IC₅₀ of 140 nM.

HY-10214

SNX-2112 3 Publications Verification PF-04928473	HSP Autophagy	Cancer
SNX-2112 (PF 04928473) is an orally active *Hsp90* inhibitor, with a K_d of 16 nM for *Hsp90* and IC₅₀s of 30 nM, 30 nM for Hsp90 α and Hsp90 β, also induces Her-2 degradation, and inhibits Grp94 and Trap-1, with IC₅₀s of 10 nM, 4.275 μM and 0.862 μM, respectively . SNX-2112 (PF 04928473) binds Hsp90 isoforms Hsp90α, Hsp90β and Hsp90b1/Grp94 with K_ds of 4 nM, 6 nM and 484 nM, respectively .

HY-10389A

Alvespimycin TFA 5+ Cited Publications 17-DMAG TFA; KOS-1022 TFA; NSC 707545 TFA	HSP	Cancer
Alvespimycin (17-DMAG) TFA is a potent inhibitor of *Hsp90, binding to Hsp90* with an EC₅₀ of 62 nM .

HY-170328

Hsp90-IN-36	HSP	Cancer
Hsp90-IN-36 (compound 5) is a *Hsp90* inhibitor with anticancer activity (MCF-7, IC₅₀=14.74 μM) .

HY-146228

HSP90-IN-13	HSP Apoptosis Topoisomerase EGFR VEGFR	Cancer
HSP90-IN-13 (compound 5k) is a highly potent *HSP90* pan inhibitor with an IC₅₀ value of 25.07 nM. HSP90-IN-13 has multi-target activity against EGFR, VEGFR-2 and Topoisomerase-2. HSP90-IN-13 causes cell cycle arrest at G2/M phase and induces apoptosis of MCF-7 cells through mitochondrial-mediated pathway .

HY-151335

KU-177	HSP	Cancer
KU-177 is a potent inhibitor of *Hsp90* ATPase homologue 1 (Aha1), ablates Aha1-driven enhancement of Hsp90-dependent tau aggregation. KU-177 also disrupts *Aha1/Hsp90* interactions (IC₅₀=4.08 μM) without inhibition of Hsp90’s ATPase activity. KU-177 can be used for tauopathies research .

HY-174347

Hsp90-Cdc37-IN-4	HSP Casein Kinase Apoptosis	Cancer
Hsp90-Cdc37-IN-4, a Celastrol (HY-13067) derivative, inhibits the Hsp90-Cdc37 protein-protein interaction (PPI). Hsp90-Cdc37-IN-4 selectively inhibits casein kinase 2 (CK2), reducing phosphorylation of its substrate Cdc37 at Serine 13. Hsp90-Cdc37-IN-4 induces G0/G1 cell cycle arrest and triggers apoptosis via the mitochondrial pathway. Hsp90-Cdc37-IN-4 demonstrates potent anti-breast cancer activity .

HY-169098

HSP90/LSD1-IN-1	HSP Histone Demethylase	Cancer
HSP90/LSD1-IN-1 (compound 6) is a *HSP90/LSD1* dual inhibitor. HSP90/LSD1-IN-1 inhibits the proliferation of prostate cancer cell lines PC-3 and DU145, with GI₅₀ values of 0.24 and 0.30 μM, respectively .

HY-158131

FKBP51-Hsp90-IN-2	FKBP HSP	Neurological Disease Cancer
FKBP51-Hsp90-IN-2 (Compound E08) is a selective *FKBP51-Hsp90* protein-protein interaction inhibitor with IC₅₀ values of 0.4 µM and 5 µM for FKBP51 and FKBP52, respectively. FKBP51-Hsp90-IN-2 also effectively stimulates cellular energy metabolism and neurite growth. FKBP51-Hsp90-IN-2 can be used in research on neurodegenerative diseases and cancer .

HY-115997

PROTAC HSP90 degrader BP3	PROTACs HSP	Cancer
PROTAC HSP90 degrader BP3 is a potent and selective degradation of *HSP90* in a CRBN-dependent fashion. PROTAC HSP90 degrader BP3 has a certain degradation effect on *HSP90* protein in MCF-7 cells (DC₅₀=0.99 μM). PROTAC HSP90 degrader BP3 inhibits the growth of breast cancer cell . PROTAC HSP90 degrader BP3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-176279

Hsp90-IN-42	HSP	Cancer
Hsp90-IN-42 (Compound 13l) is a potent heat shock protein 90 (Hsp90) inhibitor (IC₅₀=15.65 nM). Hsp90-IN-42 reduces the stability of the epidermal growth factor receptor (EGFR), suppressing the activation of the EGFR-Akt signaling pathway, inducing G0/G1 phase arrest in colorectal cancer cells (such as HT-29 cells), and slightly triggering apoptosis. Hsp90-IN-42 also inhibits cell proliferation and migration by down-regulating the expression of CDK12, CDK13, and Bcl-2 proteins, and up-regulating the expression of Bax protein. Hsp90-IN-42 is promising for research of colorectal cancer .

HY-146293

HDAC6/HSP90-IN-1	HDAC HSP	Cancer
HDAC6/HSP90-IN-1 (compound 17) is a potent and selective dual inhibitor of HDAC6 and *HSP90, with IC₅₀* values of 4.3 and 46.8 nM, respectively. HDAC6/HSP90-IN-1 down-regulates PD-L1 expression in INF-γ treated H1975 lung cancer cells. HDAC6/HSP90-IN-1 inhibits tumor growth in human H1975 xenograft mice .

HY-158130

FKBP51-Hsp90-IN-1	FKBP HSP	Neurological Disease Metabolic Disease Cancer
FKBP51-Hsp90-IN-1 (Compound D10) is a selective inhibitor of the *FKBP51-Hsp90* protein-protein interaction, with an IC₅₀ value of 0.1 μM against FKBP51. FKBP51-Hsp90-IN-1 can be used in the research of stress-related diseases, Alzheimer's disease, and metabolic disorders .

HY-12024

Alvespimycin hydrochloride 10+ Cited Publications 17-DMAG hydrochloride; KOS-1022 hydrochloride; BMS 826476	HSP Apoptosis	Cancer
Alvespimycin hydrochloride (17-DMAG hydrochloride; KOS-1022; BMS 826476) is a potent inhibitor of *Hsp90, binding to Hsp90* with EC₅₀ of 62±29 nM.

HY-175467

HDAC6/HSP90-IN-3	HSP HDAC	Cancer
HDAC6/HSP90-IN-3 (Compound 17) is an orally active dual histone deacetylase 6 (HDAC6) and heat shock protein 90 (HSP90) inhibitor with IC₅₀ values of 28 nM and 0.88 μM, respectively. HDAC6/HSP90-IN-3 is promising for research of malignant tumors such as prostate cancer .

HY-125759

3-Phenyltoxoflavin	HSP	Cancer
3-Phenyltoxoflavin, a derivative of Toxoflavin, is an *Hsp90* inhibitor, with a K_d of 585 nM for the interaction of Hsp90-TPR2A. 3-Phenyltoxoflavin has anti-cancer activity .

HY-130851

HS-27	HSP	Cancer
HS-27, a fluorescently-tethered *Hsp90* inhibitor, assays surface Hsp90 expression on intact tissue specimens. HS-27 is made up of the core elements of SNX-5422, an Hsp90 inhibitor, tethered via a PEG linker to a fluorescein derivative (fluorescein isothiocyanate or FITC), that binds to ectopically expressed Hsp90. HS-27 has potential use in a see-and-treat paradigm in breast cancer .

Cat. No.	Product Name	Type

HY-133705

Geldanamycin-FITC	Fluorescent Dyes/Probes
Geldanamycin-FITC, a Geldanamycin fluorescent probe, can be used in a fluorescence polarization assay for HSP90 inhibitors. Geldanamycin-FITC also can be used for detection of cell surface HSP90 (Ex/Em = 488/515 nm) .

HY-122878

HS-131	Fluorescent Dyes/Probes
HS-131, a near infrared dye tethered *Hsp90* inhibitor, is able to detect oncogene-driven breast cancers, including multiple different molecular subtypes of human breast cancers .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-119906

Conglobatin FW-04-806	Natural Products Microorganisms Classification of Application Fields Source classification Disease Research Fields Cancer	HSP Apoptosis
Conglobatin (FW-04-806), a macrolide dilactone, is isolated from the culture of Streptomyces conglobatus. Conglobatin is an orally active *Hsp90* inhibitor. Conglobatin can bind to the N-terminal domain of Hsp90 and disrupt Hsp90-Cdc37 complex formation. Conglobatin induces apoptosis in human breast cancer cells and esophageal squamous cell carcinoma cells, and exhibits antitumor activity in vivo .

HY-107577

Gedunin	Infection Triterpenes other families Classification of Application Fields Terpenoids Source classification Plants Inflammation/Immunology Disease Research Fields	HSP
Gedunin is a limonoid with anti-cancer, anti-viral, anti-inflammatory and insecticidal activities. Gedunin acts as a potent *Hsp90* inhibitor and induces the degradation of Hsp90-dependent client proteins. Geduni may obstructs the entry of SARS-CoV-2 virus into human host cells and can be used for COVID-19 research .

HY-15230

Geldanamycin Maximum Cited Publications 35 Publications Verification	Infection Quinones Microorganisms Classification of Application Fields Source classification Benzene Quinones Inflammation/Immunology Disease Research Fields	HSP Bacterial Influenza Virus Antibiotic
Geldanamycin is a *Hsp90* inhibitor with antimicrobial activity against many Gram-positive and some Gram-negative bacteria. Geldanamycin has anti-influenza virus H5N1 activities.

HY-N3417

Kongensin A 1 Publications Verification	Classification of Application Fields Euphorbiaceae Plants Inflammation/Immunology Disease Research Fields Croton kongensis Gagnep.	HSP RIP kinase Apoptosis Necroptosis
Kongensin A is a natural product isolated from Croton kongensis. Kongensin A is an effective, covalent *HSP90* inhibitor that blocks RIP3-dependent necroptosishas. Kongensin A is a potent necroptosis inhibitor and an apoptosis inducer. Kongensin A has potential anti-necroptosis and anti-inflammation applications .

HY-108486

Herbimycin A	Infection Quinones Microorganisms Classification of Application Fields Source classification Benzene Quinones Disease Research Fields	Bacterial Antibiotic
Herbimycin A, an ansamycin antibiotic, acts as a Src family kinase inhibitor. Herbimycin A binds to the SH domain and inhibits the activity of p60 ^v-src and p210 ^BCR-ABL Herbimycin A inhibits Hsp90 and impairs recovery from heat shock. Herbimycin A exhibits antiangiogenic activity in endothelial cells in vitro.

HY-N1455

Falcarinol Panaxynol; Carotatoxin	Natural Products Classification of Application Fields Ambrosia psilostachya DC. Source classification Umbelliferae Plants Disease Research Fields Cancer	HSP Apoptosis
Falcarinol (Panaxynol) is a natural, orally active *Hsp90* inhibitor targeting both the N-terminal and C-terminal of Hsp90 with limited toxicities. Falcarinol (Panaxynol) induces apoptosis . Falcarinol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-N10393

Vibsanin A	Natural Products Classification of Application Fields Viburnaceae Source classification Viburnum awabuki K. Koch Plants Disease Research Fields Cancer	PKC HSP
Vibsanin A, a protein kinase C (PKC) activator, exhibits anti-proliferative activity against human cancer cell lines. Vibsanin A is also a *HSP90* inhibitor .

HY-N14780

Pochonin D (+)-Pochonin D	Natural Products Microorganisms Source classification	HSP Interleukin Related Enterovirus
Pochonin D ((+)-Pochonin D) is an inhibitor of heat shock protein 90 (Hsp90) with antiviral and anti-inflammatory activities. Pochonin D inhibits Hsp90, affecting the homeostasis, folding, and assembly processes of viral proteins, reducing the replication ability of the virus. Pochonin D reduces the infiltration of inflammatory cells and the secretion of inflammatory cytokines such as TNF-α and IL-1β, alleviating the inflammatory response. Pochonin D is promising for research of Human rhinoviruses (HRV) infections and cancers .

HY-15230R

Geldanamycin (Standard)	Quinones Microorganisms Source classification Benzene Quinones	Reference Standards HSP Bacterial Influenza Virus Antibiotic
Geldanamycin (Standard) is the analytical standard of Geldanamycin. This product is intended for research and analytical applications. Geldanamycin is a *Hsp90* inhibitor with antimicrobial activity against many Gram-positive and some Gram-negative bacteria. Geldanamycin has anti-influenza virus H5N1 activities.

HY-N15154

Tasiamide B	Natural Products Marine algae Marine natural products Source classification	Cathepsin HSP
Tasiamide B is a Cathepsin D inhibitor, which is a linear peptide found in the marine cyanobacteria Symploca sp.. Tasiamide B is proved as a good template for the development of aspartic proteases inhibitors. Tasiamide B is effective against skin cancer by strongly interacting with the target protein *HSP90* .

HY-B0425A

Novobiocin sodium 5+ Cited Publications Albamycin sodium; Cathomycin sodium	Microorganisms Anti-inflammation/Immunoregulatory Classification of Application Fields Antibiotics Source classification Antiviral Antibacterial Disease Research Disease Research Fields Other Antibiotics Cancer	Bacterial Antibiotic Orthopoxvirus Apoptosis DNA/RNA Synthesis HSP
Novobiocin (Albamycin) sodium is a potent and orally active antibiotic. Novobiocin sodium also is a DNA gyrase inhibitor and a heat shock protein 90 (Hsp90) antagonist. Novobiocin sodium has the potential for the research of highly beta-lactam-resistant pneumococcal infections. Novobiocin sodium shows anti-orthopoxvirus activity .

HY-N6769

Radicicol 3 Publications Verification Monorden	Antifungal Classification of Application Fields Marine natural products Source classification Anti-parasitic Disease Research Infection Microorganisms Macrolide Antibiotics Antibiotics Phenols Polyphenols Marine microorganism Disease Research Fields	HSP Bacterial Antibiotic Parasite
Radicicol is an inhibitor of *Hsp90* with an IC₅₀ value < 1 μM, and leads to proteasomal degradation . Radicicol exhibits inhibition on PDK with IC₅₀s of 230 μM (PDK1) and 400 μM (PDK3). Radicicol is an antifungal and antimalarial antibiotic, impairs mitochondrial replication by targeting P. falciparum topoisomerase VIB . Radicicol is also an inhibitor of fat mass and obesity-associated protein (FTO), with an IC₅₀ value of 16.04 μM .

HY-N1934

Dihydroberberine	Cardiovascular Disease Alkaloids other families Classification of Application Fields Source classification Plants Isoquinoline Alkaloids Inflammation/Immunology Disease Research Fields	Potassium Channel HSP
Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .

HY-N1934R

Dihydroberberine (Standard)	Alkaloids other families Source classification Plants Isoquinoline Alkaloids	Reference Standards Potassium Channel HSP
Dihydroberberine (Standard) is the analytical standard of Dihydroberberine. This product is intended for research and analytical applications. Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .

HY-B1434

7-Aminocephalosporanic acid 2 Publications Verification 7-ACA	Infection Classification of Application Fields Disease Research Fields	Beta-lactamase Bacterial Antibiotic
7-aminocephalosporanic acid (7-ACA) is a *HSP90β* inhibitor and an antibiotic. 7-Aminocephalosporanic acid is the core chemical structure of the synthesis of cephalosporin antibiotics and an effective β-lactamase inhibitor .

Cat. No.	Product Name	Chemical Structure

HY-13757S

Tamoxifen-d3 hydrochloride

Tamoxifen-d₃ hydrochloride is deuterated labeled Tamoxifen (Citrate) (HY-13757). Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells .Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.1 μM and 1.8 μM, respectively . Tamoxifen Citrate activates autophagy and induces apoptosis .Tamoxifen Citrate also can induce gene knockout of CreER(T2) transgenic mouse .

HY-10211S

Tanespimycin-d5

Tanespimycin-d₅ (17-AAG-d₅; NSC 330507-d₅; CP 127374-d₅) is the deuterium labeled Tanespimycin (HY-10211). Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC₅₀ of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90 . Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression .

HY-13757AS1

Tamoxifen-d3

Tamoxifen-d₃ is the deuterium labeled Tamoxifen . Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells . Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen activates autophagy and induces apoptosis . Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse .

HY-W778408

Tamoxifen-13C6

Tamoxifen- ¹³C₆ (ICI 47699- ¹³C₆) is the ¹³C-labeled Tamoxifen (HY-13757A). Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells . Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.1 μM and 1.8 μM, respectively . Tamoxifen activates autophagy and induces apoptosis . Tamoxifen also can induce gene knockout of CreER transgenic mouse .

Cat. No.	Product Name		Classification

HY-117395

PU-H54		Alkynes
PU-H54, a Grp94-selective inhibitor, can be used for the research of breast cancer. Hsp90 chaperone family, comprised in humans of four paralogs, Hsp90α, Hsp90β, Grp94 and Trap-1, has important roles in malignancy . PU-H54 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-169098

HSP90/LSD1-IN-1		Alkynes
HSP90/LSD1-IN-1 (compound 6) is a *HSP90/LSD1* dual inhibitor. HSP90/LSD1-IN-1 inhibits the proliferation of prostate cancer cell lines PC-3 and DU145, with GI₅₀ values of 0.24 and 0.30 μM, respectively .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks